Literature DB >> 27932030

A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer.

Daniel Delitto1, Sarah M Judge2, Thomas J George3, George A Sarosi4, Ryan M Thomas4, Kevin E Behrns1, Steven J Hughes1, Andrew R Judge2, Jose G Trevino5.   

Abstract

BACKGROUND: The relationship between myopenia, nutritional status, and long-term oncologic outcomes remains poorly characterized in patients with clinically resectable pancreatic cancer. We sought to reliably quantify prognostic indicators of preoperative cachexia in a manner applicable to any clinical setting.
METHODS: Preoperative computed tomographies were available electronically and suitable for analysis in 73 of 82 consecutive patients with pancreatic cancer undergoing pancreatoduodenectomy between November 2010 and February 2014. The psoas index was computed from the cross-sectional area of the psoas muscles normalized to vertebral body area at the third lumbar vertebra. Correlation and proportional hazards analyses were performed to identify relationships between muscularity, preoperative nutritional markers, clinicopathologic parameters, and long-term survival.
RESULTS: The psoas index correlated strongly with preoperative hemoglobin and albumin levels (P = .001 and .014, respectively) identifying a pattern of preoperative frailty. High psoas index and the albumin and hemoglobin levels were associated with improved long-term survival (hazard ratio 0.014, P < .001; hazard ratio 0.43, P < .001; and hazard ratio = 0.80, P = .014); however, on multivariate analysis, the psoas index proved to be the only independent predictor of survival (hazard ratio 0.021; P = .003). Rapid decreases in the psoas index during neoadjuvant chemotherapy were associated with poor postoperative outcomes, as were decreases in the psoas index during the postoperative period.
CONCLUSION: The data indicate that the psoas index, a calculation derived from a clinically mandated, preoperative computed tomography, is a statistically powerful and easily calculated predictor of survival in pancreatic cancer when compared to tumor grade and stage as well as previously validated nutritional parameters.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27932030     DOI: 10.1016/j.surg.2016.09.038

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  16 in total

Review 1.  Prognostication in advanced cancer: update and directions for future research.

Authors:  David Hui; Carlos Eduardo Paiva; Egidio G Del Fabbro; Christopher Steer; Jane Naberhuis; Marianne van de Wetering; Paz Fernández-Ortega; Tatsuya Morita; Sang-Yeon Suh; Eduardo Bruera; Masanori Mori
Journal:  Support Care Cancer       Date:  2019-03-13       Impact factor: 3.603

2.  Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle.

Authors:  Rachel L Nosacka; Andrea E Delitto; Dan Delitto; Rohan Patel; Sarah M Judge; Jose G Trevino; Andrew R Judge
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-02-10       Impact factor: 12.910

3.  Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities.

Authors:  Jennifer B Permuth; Ashley Clark Daly; Daniel Jeong; Jung W Choi; Miles E Cameron; Dung-Tsa Chen; Jamie K Teer; Tracey E Barnett; Jiannong Li; Benjamin D Powers; Nagalakshmi B Kumar; Thomas J George; Karla N Ali; Tri Huynh; Shraddha Vyas; Clement K Gwede; Vani N Simmons; Pamela J Hodul; Estrella M Carballido; Andrew R Judge; Jason B Fleming; Nipun Merchant; Jose G Trevino
Journal:  Cancer Med       Date:  2019-05-09       Impact factor: 4.452

4.  Circulating miR-203 derived from metastatic tissues promotes myopenia in colorectal cancer patients.

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Keun Hur; Akira Yamamoto; Chengzeng Yin; Shozo Ide; Takahito Kitajima; Hiroyuki Fujikawa; Hiromi Yasuda; Yuhki Koike; Yoshiki Okita; Junichiro Hiro; Shigeyuki Yoshiyama; Toshimitsu Araki; Chikao Miki; Donald C McMillan; Ajay Goel; Masato Kusunoki
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-03-25       Impact factor: 12.910

5.  Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine.

Authors:  Michael H Gerber; Patrick W Underwood; Sarah M Judge; Daniel Delitto; Andrea E Delitto; Rachel L Nosacka; Bayli B DiVita; Ryan M Thomas; Jennifer B Permuth; Steven J Hughes; Shannon M Wallet; Andrew R Judge; Jose G Trevino
Journal:  Int J Mol Sci       Date:  2018-12-01       Impact factor: 5.923

6.  Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival.

Authors:  Sarah M Judge; Rachel L Nosacka; Daniel Delitto; Michael H Gerber; Miles E Cameron; Jose G Trevino; Andrew R Judge
Journal:  JNCI Cancer Spectr       Date:  2018-08-06

7.  IL-8 Released from Human Pancreatic Cancer and Tumor-Associated Stromal Cells Signals through a CXCR2-ERK1/2 Axis to Induce Muscle Atrophy.

Authors:  Chandler S Callaway; Andrea E Delitto; Rohan Patel; Rachel L Nosacka; Andrew C D'Lugos; Daniel Delitto; Michael R Deyhle; Jose G Trevino; Sarah M Judge; Andrew R Judge
Journal:  Cancers (Basel)       Date:  2019-11-25       Impact factor: 6.639

8.  Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.

Authors:  Christelle d'Engremont; Julienne Grillot; Julie Raillat; Dewi Vernerey; Lucine Vuitton; Stéphane Koch; Célia Turco; Bruno Heyd; Guillaume Mouillet; Quentin Jacquinot; Christophe Borg; Angélique Vienot
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

9.  Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.

Authors:  Susan C Kandarian; Rachel L Nosacka; Andrea E Delitto; Andrew R Judge; Sarah M Judge; John D Ganey; Jesse D Moreira; Robert W Jackman
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-09-30       Impact factor: 12.910

10.  Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation.

Authors:  Patrick Naumann; Jonathan Eberlein; Benjamin Farnia; Jakob Liermann; Thilo Hackert; Jürgen Debus; Stephanie E Combs
Journal:  Cancers (Basel)       Date:  2019-10-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.